Clinical Trial Update: Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Hulio (adalimumab biosimilar) to Humira evaluates pharmacokinetics, efficacy, safety and immunogenicity to support interchangeability in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• HULIO (ADALIMUMAB-FKJP)
• Humira (adalimumab)

Snippet

Sponsor: Biocon Biologics Inc. | Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2024-10-15